Your browser doesn't support javascript.
loading
Immunohistochemical Evaluation of PARP and Caspase-3 as Prognostic Markers in Prostate Carcinomas.
Acar, Vitoria; Couto Fernandez, Fabio Leite; Buscariolo, Fabio Fabian; Novais, Adriana Alonso; Matheus Pereira, Roseli Aparecida; de Campos Zuccari, Debora Aparecida Pires.
Afiliação
  • Acar V; Academic Student, São José do Rio Preto Medical School - FAMERP.
  • Couto Fernandez FL; Department of Clinical Medicine, São José do Rio Preto Medical School - FAMERP.
  • Buscariolo FF; Academic Student, São José do Rio Preto Medical School - FAMERP.
  • Novais AA; Post-doctoral student, Cancer Molecular Research Laboratory, São José do Rio Preto Medical School - FAMERP.
  • Matheus Pereira RA; Department of Nursing, São José do Rio Preto Medical School - FAMERP.
  • de Campos Zuccari DAP; Department of Molecular Biology, São José do Rio Preto Medical School - FAMERP debora.zuccari@famerp.br.
Clin Med Res ; 19(4): 183-191, 2021 12.
Article em En | MEDLINE | ID: mdl-34933951
ABSTRACT
Prostate cancer is the second most common neoplasm among men, with a high mortality rate in advanced stages. Poly (ADP-ribose) polymerase (PARP) plays an important role in repair to DNA damage, being associated with resistance to tumor cell death. Conversely, Caspase-3 is a crucial mediator of programmed cell death, being highly expressed in apoptotic cells. The aim of the present study was to characterize the expression of PARP and Caspase-3 by immunohistochemistry in patients with advanced prostate cancer. PARP and Caspase-3 were independently correlated to patients' evolution, in accordance with the classification of prognostic groups. The increase in PARP expression was positively correlated with tumor patients with poor prognosis (P < 0.0001). In contrast, a decrease in Caspase-3 expression was identified in patients with poor prognosis, when compared with prostate cancer patients with good prognosis (P = 0.0007). Numerically, 92.3% of patients previously classified with poor prognosis showed higher PARP expression, while 93.75% of patients previously classified with good prognosis showed higher levels of Caspase-3. We conclude that PARP and Caspase-3 are potential prognostic markers for prostate cancer patients with different prognosis.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Inibidores de Poli(ADP-Ribose) Polimerases Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans / Male Idioma: En Revista: Clin Med Res Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Inibidores de Poli(ADP-Ribose) Polimerases Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans / Male Idioma: En Revista: Clin Med Res Ano de publicação: 2021 Tipo de documento: Article